Biomarker identified for likely aggressive, early stage breast cancer
 

The one-size-fits-all approach to early stage breast cancer creates a paradox: Millions of dollars are spent on unnecessary surgeries and radiation to treat women with low-risk 'in situ' lesions...

More...